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Genetics, genetic testing and sports: Aspects from sports cardiology 
 
HERBERT LÖLLGEN AND RUTH LÖLLGEN1 
Abstract 
There is a major trade-off between improvements in longevity, general health, fitness 
and quality of life due to regular intense physical activity on the one hand and 
possible cardiac risks on the other hand, whether for participants in leisure time sports 
activities or for highly trained athletes. Cardiac complications and sudden death in 
sports, even though rare, but dramatic, events, are mainly observed in those suffering 
from inherited, often latent diseases with a strong genetic background, unknown to the 
subjects. Sedentary lifestyle together with more than one risk factor may also 
contribute to cardiac events in persons beginning to exercise for the first time or 
recommencing intense physical activities after a long pause. 
 
Manifestations of inherited cardiac diseases with a typical genetic component may 
occur in children or adolescents, but also in adults. For many inherited cardiac 
diseases there is a large body of knowledge on the genetic origin, therefore, genetic 
testing may be a valuable tool for diagnosis and prevention of underlying diseases, 
especially as genetic testing has become much cheaper over the last few years. 
 
The present paper describes cardiac diseases with genetic disposition and related 
genetic testing and presents recommendations for genetic examinations. Testing 
should be of benefit for sportsmen and women but also for family members to prevent 
fatal cardiac events. These recommendations will consider benefits for the sports 
person, and ethical reflections as well. 
Introduction 
There is a large body of literature indicating that regular physical activity is of benefit 
to healthy people2 as well as those with diseases.3,4 Motivation to engage in regular 
activity can be difficult to achieve in patients and elderly persons. Commencing a 
programme of physical activity may be further complicated by an increased risk of 
cardiovascular events,5,6 especially if the physical activity is intensive, but even if it is 
only moderate. This is due to underlying cardiovascular risk factors or due to latent 
and undetected diseases of genetic origin.  
 
Studies have examined sudden cardiac arrest and even death in highly trained younger 
or older athletes, also observed in leisure time physical activity.7 It is generally 
assumed that these trained athletes, showing no signs or symptoms, are healthy. 
However, some inherited diseases may cause greater susceptibility for sudden cardiac 
emergencies, sometimes not detected in pre-participation examination.8,9,10 In many of 
these diseases, genetic analysis is appropriate to detect and identify the underlying 
mechanisms of the fatal event. The cardiac arrest in these fatal events is a combination 
of triggers for arrhythmias, underlying cardiac disease and/or unstable 
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electrophysiological substrates due to either hidden “electrical” or heart muscle 
disease. 11,12,13 
Table 1: Inherited Cardiac Diseases with Genetic Causes 




Catecholaminergic polymorphic ventricular tachycardia (CPVT) 
Cardiac conduction disease (CCD) 
(WPW-Syndrome) 
Atrial fibrillation 
Cardiac Muscular Diseases 
Hypertrophic obstructive or non-obstructive Cardiomyopathy 
Dilated cardiomyopathy (familial) 
Arrythmogenic right ventricular dysplasia or Cardiomyopathy 
(Arrhythmogenic left ventricular dysplasia) 




Coronary artery disease  
 
Guidelines for genetic testing are presented as a part of the armamentarium of 
diagnosis and screening.14,15,16,17,18,19 Interpretation of the results of genetic testing is 
complex and requires close cooperation between a patient’s sports physician, 
cardiologist and a genetic expert. Testing results have to be interpreted in the 
complete context of history, clinical findings, phenotype and potential cardiac risk. 
Special questions arise with genetic testing in children, where mental health and age 
should be considered by a specialist for genetic diseases.20,21 Genetic testing can 
provide information which informs lifestyle recommendations with special regards to 
physical activity.22,23, 24,25 Recommendations for genetic testing should follow the 
evidence-based criteria of consensus documents, such as the position statement of the 
European Society of Cardiology (ESC) working group on genetic counselling and 
testing in cardiomyopathies; another example is the expert consensus statement on the 
state of genetic testing for the channelopathies and cardiomyopathies by the Heart 
Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 26,27 
Cardiac diseases with genetic components 
Inherited cardiac diseases with demonstrated underlying genetic causes have been 
termed “electric” diseases, or channelopathies or ion-channel diseases and cardiac 
muscular diseases, mainly cardiomyopathies (see Table 1). 28,29,30,31 This review gives 
information on some but not all inherited diseases as typical examples.  
Epidemiology  
The overall prevalence of inherited cardiac diseases with underlying genetic causes is 
low, but varies in different countries and among different ethnic groups: Hypertrophic 
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cardiomyopathy is approximately 1:500 but higher in African-American men32, 
ARVD is about 1:1000 but with more frequent prevalence in Italy. Ion-Channel-
diseases LQT, Brugada Syndrome and, CPVT are each about 1:2000.33,34,35,36,37,38 
Long-QT-Syndrome (LQT) 
LQT-Syndrome can be differentiated into more than eight subtypes according to the 
underlying chromosomal locus. 
Table 2: Examples of some genetic loci and genes in inherited cardiac disease with 
normal heart-structure (A: Autosomal, D: Dominant; R: Recessive. RBBB: Right 







e   






























































LQT 1, 2 and 3 are of clinical relevance.40,41,42,43,44 Diagnosis is based on clinical 
syndrome, syncopes in history and on typical changes in the resting ECG with 
prolonged QT-duration. Diagnostic criteria are based on a score system and are shown 
in Table 3, giving an example how to proceed if the ECG is suspicious. According to 
score of positive points, diagnosis can be established with low or high probability. 
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> 480 ms: 3 points 
 > 460-470: 2 points 
 > 450 (male): 1 point 
  
Torsade de pointes 2 points 
T-wave alternans positive 1  point 
T-wave abnormality > 3 leads: 1  point 
Rel. Bradycardia 0.5  point 
Syncope with stress 2  points 
  without 1  point 
Inborne deafness 0.5  point 
Family history with long QT: 1 point; with sudden death: 0.5 
point 
 
Results: > 4 points: high;  < 1 point: low probability of LQT 
 
 
LQT type 1-3 have different but typical triggers provoking arrhythmias, mostly 
ventricular arrhythmias degenerating into ventricular fibrillation and cardiac arrest. 
Type 1 (35%, gene symbol: KCNQ1) is mainly provoked by swimming, diving or 
exertion. Ackerman et al.46 posit that about 30 per cent of drownings in children or 
adolescents are due to undetected LQT1-syndrome rather than to accident. 
Arrhythmias in type 2 (about 30%, gene symbol: KCNQH2) can be provoked by 
auditory triggers. Type 3 (gene symbol SCN5A, 10%) responds to acute stress or 
occur spontaneously during sleep.47,48,49,50,51 This is known for example from sudden 
infant death. All drugs prolonging QT-duration should be avoided, and swimming and 
competitive sport is not recommended for those with LQT1. 
 
Recommendations on genetic testing are shown in Table 7 (below). The Long-QT-
Syndrome is one entity of the channelopathies which should undergo genetic testing. 
This may give important prognostic information and indicate therapeutic 
consequences in the patients as well in family members.52,53,54 
Short QT-Syndrome 
Short QT-Syndrome with 3 subtypes has been recently reported as another inherited 
cardiac disease with normal heart appearance (KCNH2, KCNQ1, KCNJ2). Diagnosis 
is based on ECG recording with short QT-duration and in some patients with typically 
elevated T-waves. Electrophysiological analysis is strongly recommended, ICD 
implantation is indicated if VF can be easily provoked. Competitive sports are not 
recommended. Genetic loci and genes and genetic testing or screening 
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This syndrome has been described by the Brugada brothers and seems to occur more 
often than previously assumed. This syndrome appears with a suspicious right bundle 
branch block (Fig. 1).  
 
Diagnosis is based on provocation with Ajmalin with typical ECG change.59,60,61 
According to ECG recordings, three modalities have been reported with differing 
ECG appearance.62 In athletes, Brugada syndrome is treated with an ICD after 
survived sudden death and also with occurrence of complex ventricular 
arrhythmias.63,64 Competitive sports are not recommended. Some drugs, fever or high 
temperature and electrolyte disturbances should be avoided.65 Evidence-based 
procedure has been reported.66,67,68,69,70 Indications for genetic testing in Brugada-
Syndrome are shown in Table 7. Due to the high risk of fatal events and possible 
lethal arrhythmias, detailed examinations are recommended and genetic testing may 
be generously indicated. 
 
Fig. 1: Young soccer player with multiple syncopes, one with fever which led to the 
presentation at the emergency department. Suspicious right bundle branch block 
(above), 25mg of Ajmalin (below) unmasked the typical picture of coved ST-





Catecholaminergic polymorphic ventricular tachycardia (CPVT) 
CPVT, first described by Coumel 1978,71 leads to deleterious cardiac events typically 
during strenuous exercise. Therefore, stress testing for diagnostic purpose should be 
performed up to real exhaustion thus provoking ventricular arrhythmias. In some 
cases, emotional stress may also lead to arrhythmias. EPS is negative in most patients. 
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Therapy starts with ß-receptor blockers, competitive sports is not allowed, if 
ventricular arrhythmias do occur. Implantation of an ICD is frequently recommended 
with ß-blockers to be continued. Recommendations for genetic testing are shown in 
Table 7. 
WPW (Wolff- Parkinson- White -Syndrome or Preexcitation Syndrome) 
Recent studies discuss whether WPW-Syndrome may in part be of genetic origin.72 
However, at the moment, there is no indication for genetic testing. Diagnostic 
procedure is standardised. In athletes with frequent episodes of supraventricular 
tachycardia, EPS is indicated and ablation of the accessory pathway should be 
considered. The ablation is so far of very low risk and the benefit for the athlete very 
high. If intermittent atrial fibrillation is present or has been documented, ablation is 
absolutely indicated as this combination may lead to ventricular fibrillation and 
sudden cardiac arrest.73,74 75,76,77,78 
Atrial Fibrillation 
Atrial fibrillation has gained a lot of attention as some authors reported a higher 
frequency of this arrhythmia in endurance athletes or in some former athletes.79, 80 
Two mechanisms are discussed: first, there might be some kind of right ventricular 
“fatigue” or reduced ejection fraction. On the other hand, there might be so-called 
vagus induced atrial fibrillation which occurs at night when heart rate drops below 40 
bpm, as is present in highly trained endurance athletes. However, there is no unique 
explanation why this is observed in one athlete and not in others with similar cardiac 
resting function.81,82 
 
As some studies point out that atrial fibrillation is more frequent in some families, an 
inherited component should be considered. A range of genetic testing has been done; 
there is no indication for routine gene examination but it may be performed for 
research purposes in a larger cohort.83 
Hypertrophic Cardiomyopathy (HCM) 
This disease is the most frequent cause of death among US athletes, especially 
African-Americans. Similarly, the disease is seen in soccer players from African 
countries playing for European clubs. Pre-participation examination is mandatory in 
Europe under FIFA (the international football association) recommendations,  
including ECG and echocardiography. Athletes with moderate to severe outflow tract 
obstruction are not allowed to participate in competitive sport. Arrhythmias are 
secondary to reduced cardiac output in hypertrophic obstructive cardiomyopathy 
(HOCM) during exercise, with reduced flow through the obstructed left ventricular 
outflow tract. In the non-obstructed left ventricle, the relative coronary microvascular 
flow impairment depends on the grade of left ventricular hypertrophy and the 
intensity of exertion. 
 
Diagnosis of H(O)CM is based on echocardiographic findings. In some athletes, 
magnetic resonance imaging provides accurate assessment of cardiac structure to 
confirm (or exclude) hypertrophy of the left ventricle or the interventricular septum. 
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Genetic testing is rarely needed in athletes with positive findings (positive 
phenotype), but may be helpful in borderline structure and in familial examination 
(see Table 7). Table 4 gives a flow chart for evaluation the subject with HCM and 
family members.84,85,86,87,88,89,90 





Control Symptoms Risk strati fication Counselling/Screening 
 







Consider ICD if risk 
factors are present 
 
 






Arrythmogenic right ventricular dysplasia or cardiomyopathy (ARVD) 
ARVD has a long history. The first description was published by Lancisi in Rome in 
1723. ARVD is more prevalent in Italy than in other countries. The diagnostic 
findings are outlined in Tables 5 and 6. The diagnostic criteria are differentiated into 
major and minor signs and symptoms.93 These criteria should be strictly analysed, 
completely and critically, to avoid misdiagnosis.94 
Table 5: Arrythmogenic right ventricular dysplasia (ARVD): When to look for ARVD? 
Two or more signs such as: 
- Sustained or non-sustained ventricular tachycardia with left bundle branch 
type  
- Negative. T- wave in lead V1-V3,  
- Enlarged right ventricle with contraction abnormality, 
- Positive late potentials (SAECG),  
- Family history with positive findings (early) 
- sudden unexplained death) 
- Definite diagnosis is based on minor and major criteria95
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Table 6: Diagnostic procedure in ARVD96 
Diagnostic criteria are divided in major and minor criteria: 
Main findings are : 
History: Sudden death in the family 
ECG: Disturbed depolarisation and conduction (epsilon-wave) 
• Repolarisation abnormalities : negative T-wave) 
• Ventricular arrhythmias (VT), PVB 
Echo: Global or regional contraction abnormalities of the right 
ventricle 
Biopsy: Fiber-fatty degeneration of the myocardial tissue  
Echocardiography and magnetic resonance imaging with typical 
findings 
 
MRI is a significant method with which to confirm diagnosis, but history, clinical 
examination, non-invasive imaging (e.g. echocardiography), electrophysiological 
stimulation (EPS) and myocardial biopsy, if necessary, should be included in the 
diagnostic procedure.97,98,99,100,101,102,103. A new diagnostic test with improved 
sensitivity has recently been published.104 Once the diagnosis is established, 
competitive sports should be avoided and ICD – implantation has to be considered if 
necessary.105,106 Genetic testing may be carried out for members of the family or if 
clinical findings are borderline.107,108,109 
Left ventricular non-compaction cardiomyopathy (NCCM) 
This is a rather rare clinical entity and diagnosis and genetic testing should be 
performed according to the guidelines and recommendations respectively. Three 
genes have more commonly been associated: TAZ (Xp28), DTNA and LDB3 with 
frequent familiar recurrence.110 
 
Non-compaction cardiomyopathy often leads to heart failure. Therapy should follow 
established guidelines. Recommendation on competitive sports depends on the degree 
of reduced ejection fraction. Genetic testing of patient’s relatives is strongly 
recommended. 
Comments on Genetic Testing 
Genetic testing in all patients or athletes is based on an individual cascade screening. 
In HCM, for example, benefits of genetic testing are to get a “definitive diagnosis and 
identification of at-risk family members”,111 confirmation of diagnosis and genetic 
cause of hypertrophy and, in terms of research, to “gain greater understanding of 
fundamental disease biology”.112 The limitations of genetic testing should be 
considered, including: clinical yield non-informative results, mutation not identified, 
limited clinical impact and ambiguous results (modified from Ho 2012113). Results of 
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The position statement of the ESC refers to some key messages (modified from Crotti 
2010115): 
 Genetic origin of e.g. cardiomyopathy 
 Mode of inheritance, risk of transmission 
 Clinical manifestation, natural history 
 Benefits of screening within the family 
 Risk of worsening during pregnancy 
 Availability and scope of molecular/genetic testing 
 Appropriate patient organisation 
 Medical sources of organisation 
 Information about the referral centre 
 
Information about all of these should be given during genetic counselling. The 
protocol of this counselling should contain: the name of the person who receives the 
counselling, time of counselling, results of genetic testing and predictive diagnosis 
which have been given to the patient (athlete) (see position statement116,117). The key 
messages clearly demonstrate that consultation with a trained professional with expert 
knowledge is needed by each individual. The social background also has to be taken 
into consideration as the consequences for each family member are considerable. 
Risk stratification 
There is an increasing interest in the risks and benefit of regular and intense physical 
activity or competitive sports.118,119,120,121,122,123,124,125,126,127 Certain registers collate 
the frequency of and association with type of sport of fatal events.128 Pre-participation 
examination is under discussion, as is whether or not resting ECG should be included. 
There are some findings indicating that examination with ECG may reduce sudden 
death in sport.129 One research study in Germany clearly showed that many 
participants in long distance running had not undergone medical examination before 
taking up the sport.130 
 
Many factors favour cardiac complications during physical activity.131 Bursts of 
exertion, adverse environmental conditions (heat, cold), prolonged endurance in 
activities such as triathlon or marathon, electrolyte disturbances, stress, in some kinds 
of sports (such as hang gliding or bungee jumping), acute or chronic drug abuse 
(including doping), and finishing with higher intensity all predispose to adrenergic 
stimulation, thus enhancing pro-arrhythmogenic effects. 
 
A number of deaths during exercise or in athletes have been associated with genetic 
cardiovascular disease. These genetic components together with above mentioned 
factors are responsible for a substantial proportion of unexpected cardiac events and 
deaths during adolescence and young adulthood.132,133,134 Pre-participation 
examination, including resting ECG, is strongly recommended, as is the continuing 
education of sports physicians and cardiologists about inherited diseases, and this will 
be offered in Europe in the near future. 
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Professional qualification and cooperation with specialists 
Exercise testing in older sportspeople should be performed according to existing 
guidelines. Nonetheless, the physician performing the examination should be aware of 
inherited diseases; (s)he should be trained as a sports cardiologist with special training 
in ECG interpretation. The physician or sports cardiologist should closely cooperate 
with genetic diagnostics and diseases specialists. Genetic testing too should follow the 
recommendations.135 
 
As diagnostic tests become cheaper, insurance companies should in the future pay for 
genetic diagnosis (in accordance with guidelines) in order to prevent complications in 
young people and especially in genetically disposed families. Negative results in 
genetic testing do not exclude established clinical diagnosis as test results have a 
sensitivity ranging between 26-70 per cent. 136 Detected mutations should be 
considered in tandem with the clinical findings. 
 
Finally, in the case of sudden unexplained death in the context of sport or physical 
exertion, molecular autopsy should be a standard to evaluate for a definitive 
diagnosis, and not only for research purposes.137 This procedure gives reliable results 
for family members and findings which could help other sportswomen and sportsmen 
in the future. 
Conclusion 
At present, genetic screening is recommended to protect the athlete from cardiac risks 
if the diagnostic findings are borderline. If the clinical diagnosis is unequivocal, 
testing may only be useful for family members or appropriate relatives. Clinical 
examination must be the first step with treatment of symptoms, if present. Risk 
stratification of complications such as cardiac arrest is the next step, according to 
numbers of risk factors, followed by lifestyle and physical activity recommendations. 
Family screening should be performed according to the guidelines to prevent fatal 
events in relatives and genetic experts should be involved. Existing recommendations 
and guidelines support this basic procedure in these examinations.138,139,140,141 
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Table 7: Recommendations for Genetic Testing in Cardiac Genetic Diseases 
(Extract modified from existing guidelines142) 
STATE OF GENETIC TESTING FOR LONG QT SYNDROME (LQTS) 
Class I (is recommended) 
Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing 
is recommended for any patient in whom a cardiologist has established a strong clinical 
index of suspicion for LQTS based on examination of the patient’s clinical history, family 
history, and expressed electrocardiographic phenotype (resting 12-lead ECG and/or 
provocative stress testing with exercise or catecholamine infusion). 
Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing 
is recommended for any asymptomatic patient with QT prolongation in the absence of other 
clinical conditions that might prolong the QT interval (such as electrolyte abnormalities, 
hypertrophy, bundle branch block, etc., i.e., otherwise idiopathic) on serial 12-lead ECG 
defined as QTc.480 ms (prepuberty) or 0.500 ms (adults). 
Mutation-specific genetic testing is recommended for family members and other appropriate 
relatives subsequently following the identification of the LQTS-causative mutation in an 
index case. 
Class IIb (may be considered) 
Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing 
may be considered for any asymptomatic patient with otherwise idiopathic QTc values .460 
ms (prepuberty) or .480 ms (adults) on serial 12-lead ECG. 
STATE OF GENETIC TESTING FOR CATECHOLAMINERGIC POLYMORPHIC 
VENTRICULAR TACHYCARDIA (CPVT) 
Class I (is recommended) 
Comprehensive or CPVT1 and CVPT2 (RYR2 and CASQ2) targeted CPVT genetic testing 
is recommended for any patient in whom a cardiologist has established a clinical index of 
suspicion for CPVT based on examination of the patient’s clinical history, family history, 
and expressed electrocardiographic phenotype during provocative stress testing with cycle, 
treadmill, or catecholamine infusion. 
Mutation-specific genetic testing is recommended for family members and appropriate 
relatives following the identification of the CPVT-causative mutation in an index case. 
STATE OF GENETIC TESTING FOR BRUGADA SYNDROME (BrS) 
Class I (is recommended) 
Mutation-specific genetic testing is recommended for family members and appropriate 
 relatives following the identification of the BrS-causative mutation in an index case. 
Class IIa (can be useful) 
Comprehensive or BrS1 (SCN5A) targeted BrS genetic testing can be useful for any patient 
in whom a cardiologist has established a clinical index of suspicion for BrS based on 
examination of the patient’s clinical history, family history, and expressed 
electrocardiographic (resting 12-lead ECG and/or provocative drug challenge testing) 
phenotype. 
Class III (is not indicated/recommended) 
Genetic testing is not indicated in the setting of an isolated type 2 or type 3 Brugada ECG 
pattern. 
STATE OF GENETIC TESTING FOR HYPERTROPHIC CARDIOMYOPATHY 
(HCM) 
Class I (is recommended) 
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Comprehensive or targeted (MYBPC3, MYH7, TNNI3, TNNT2, TPM1) HCM genetic 
testing is recommended for any patient in whom a cardiologist has established a clinical 
diagnosis of HCM based on examination of the patient’s clinical history, family history, and 
electrocardiographic/echocardiographic phenotype. 
Mutation-specific genetic testing is recommended for family members and appropriate 
relatives following the identification of the HCM-causative mutation in an index case. 
STATE OF GENETIC TESTING FOR ARRHYTHMOGENIC 
CARDIOMYOPATHY (ACM) 
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC) 
Class I (is recommended) 
Mutation-specific genetic testing is recommended for family members and appropriate 
relatives following the identification of the ACM/ARVC causative mutation in an index 
case. 
Class IIa (can be useful) 
Comprehensive or targeted (DSC2, DSG2, DSP, JUP, PKP2, and TMEM43) ACM/ARVC 
genetic testing can be useful for patients satisfying task force diagnostic criteria for 
ACM/ARVC. 
Class IIb (may be considered) 
Genetic testing may be considered for patients with possible ACM/ARVC (1 major or 2 
minor criteria) according to the 2010 task force criteria (European Heart Journal). 
Class III (is not indicated/recommended) 
Genetic testing is not recommended for patients with only a single minor criterion according 
to the 2010 task force criteria. 
STATE OF POST-MORTEM GENETIC TESTING IN SUDDEN UNEXPECTED 
DEATH CASES (SUD/SIDS) 
Class I (is recommended) 
For all SUDS and SIDS cases, collection of a tissue sample is recommended (5–10 mL 
whole blood in EDTA tube, blood spot card, or a frozen sample of heart, liver, or spleen) for 
subsequent DNA analysis/genetic testing. 
Mutation-specific genetic testing is recommended for family members and other appropriate 
relatives following the identification of a SUDS causative mutation in the decedent. 
Class IIb (may be considered) 
In the setting of autopsy negative SUDS, comprehensive or targeted (RYR2, KCNQ1, 
KCNH2, and SCN5A) ion channel genetic testing may be considered in an attempt to 
establish probable cause and manner of death and to facilitate the identification of 
potentially at-risk relatives and is recommended if circumstantial evidence points toward a 
clinical diagnosis of LQTS or CPVT specifically (such as emotional stress, acoustic trigger, 
drowning as the trigger of death. 
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